Valuation
- Market cap
- 842,256,000
- Revenue TTM
- $407,320,000
- Net income TTM
- $-61,600,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -15.12%
- Debt to equity
- 1.69
Trading
- Volume
- 4,092,100
- Avg volume
- 4,360,338
- Day's range
- $3.29 – $3.40
- Shares out
- 249,188,000
- Stochastic %K
- 15%
- Beta
- 0.68
- Analysts
- Strong Sell
- Price target
- $12.90
Company profile
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, I...
Show more
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 510 745 1700
- Website
- https://www.ardelyx.com
- Address
- 400 Fifth Avenue, Suite 210, Waltham, United States
Latest news
No headlines yet.
